UC Patients Taking Ozanimod in Phase 2 Trial Show Histologic Improvement, Celegene Reports

UC Patients Taking Ozanimod in Phase 2 Trial Show Histologic Improvement, Celegene Reports
Celgene International Sàrl, a subsidiary of Celgene Corporation, has announced the release of additional data on exploratory endpoints from its Phase 2 clinical trial assessing ozanimod in people with moderate to severe ulcerative colitis (UC). The data, showing improvements in histologic measures and remission, was presented at the recent 11th Congress of the European Crohn’s and Colitis Organization (ECCO) in Amsterdam. Ozanimod is a small molecule sphingosine 1-phosphate (S1P) 1 and 5 receptor modulator in development for immune-inflammatory indications. Treatment with S1P receptor modulators is designed to work
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *